<DOC>
	<DOCNO>NCT01022723</DOCNO>
	<brief_summary>To evaluate efficiency microdevice circulate tumor cell isolation correlate circulate titre response progression .</brief_summary>
	<brief_title>Clinical Validation Microfluidic Device Isolation Molecular Characterization Circulating Tumor Cells</brief_title>
	<detailed_description>- Validate clinical use mircofluidic device capture circulate timor cell broad range tumor type - Characterize identify circulate tumor cell demostrate cell viability capture method - Apply technology clinically relevant setting correlate response treatment disease progression - Elucidate predictive pharmacodynamic biomarkers context early phase trial novel therapeutic</detailed_description>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Patients newly diagnose metastatic disease plan palliative chemotherapy Tumor type specify : non smoker lung adenocarcinoma , undifferentiated EBVISH positive nasopharyneal carcinoma , breast cancer , colorectal cancer , prostate cancer , gastric cancer Informed consent give purpose blood sample study Measurable disease RECIST criterion least 1cm preferred sine qua non study accrual</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Circulating tumor cell</keyword>
	<keyword>metastasis</keyword>
	<keyword>cancer</keyword>
	<keyword>cell isolation</keyword>
	<keyword>mircofludics</keyword>
	<keyword>cell detection</keyword>
</DOC>